In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer,
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …

Metastatic cancer is almost always terminal, and more than 90% of cancer deaths result from
metastatic disease. Combating cancer metastasis and post-therapeutic recurrence …

Epithelial ovarian cancer (EOC) represents a heterogeneous spectrum of disease entities at
a clinical, pathological and molecular level. Ovarian cancer is the second most lethal …

Highlights•46 participants from 15 countries across Europe, Asia and the USA contributed to
the ESGO–ESMO–ESP consensus conference.•Recommendations cover diagnosis and …

Background Treatment for patients with recurrent ovarian cancer has been mainly based on
systemic therapy. The role of secondary cytoreductive surgery is unclear. Methods We …

Background In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus
bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly …

Ovarian carcinoma is characterized by heterogeneity at the molecular, cellular and
anatomical levels, both spatially and temporally. This heterogeneity affects response to …

PURPOSE To evaluate the addition of the humanized monoclonal antiprogrammed death
ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and …

Tumor vascularization occurs through several distinct biological processes, which not only
vary between tumor type and anatomic location, but also occur simultaneously within the …

Background Olaparib has shown significant clinical benefit as maintenance therapy in
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …